| scholarly article | Q13442814 |
| P50 | author | Tessa Holyoake | Q34004355 |
| Paolo Gallipoli | Q57008240 | ||
| Koorosh Korfi | Q57235267 | ||
| David Vetrie | Q37390064 | ||
| Anuradha Tarafdar | Q38321037 | ||
| Alison M Michie | Q38321055 | ||
| Lisa E M Hopcroft | Q50044548 | ||
| P2093 | author name string | Alan Hair | |
| Heather G Jørgensen | |||
| Francesca Pellicano | |||
| Jennifer Cassels | |||
| P2860 | cites work | JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin | Q24318979 |
| Janus kinases in immune cell signaling | Q24322021 | ||
| Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 | ||
| Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells | Q28276260 | ||
| Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile | Q28294205 | ||
| MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers | Q28306431 | ||
| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia | Q29614280 | ||
| Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation | Q30167883 | ||
| Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis | Q33429617 | ||
| Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells | Q33526746 | ||
| Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter | Q33965074 | ||
| Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. | Q33996893 | ||
| Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination. | Q54652584 | ||
| TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. | Q55478696 | ||
| Regulation of MHC class II expression in human T-cell malignancies | Q79175851 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 | ||
| JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. | Q34106870 | ||
| Jak2 is involved in c-Myc induction by Bcr-Abl | Q34153616 | ||
| Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect | Q34301568 | ||
| Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia | Q35903505 | ||
| Regulation of MHC class II gene expression by the class II transactivator | Q36274925 | ||
| Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA. | Q36363840 | ||
| The central role of CD4(+) T cells in the antitumor immune response | Q36401381 | ||
| Epigenetic regulation of MHC-II and CIITA genes | Q36548065 | ||
| Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis | Q36624165 | ||
| In vitro induction of myeloid leukemia-specific CD4 and CD8 T cells by CD40 ligand-activated B cells gene modified to express primary granule proteins | Q36628925 | ||
| Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex | Q36697774 | ||
| PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells | Q37200863 | ||
| Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. | Q37487526 | ||
| Autocrine TNF-α production supports CML stem and progenitor cell survival and enhances their proliferation | Q37635609 | ||
| Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells | Q38806235 | ||
| Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population | Q38850383 | ||
| TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia | Q39744014 | ||
| Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. | Q40507425 | ||
| CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter | Q40795943 | ||
| Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects | Q40936847 | ||
| Class II transactivator and class II MHC gene expression in microglia: modulation by the cytokines TGF-beta, IL-4, IL-13 and IL-10. | Q40956460 | ||
| P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members | Q41145752 | ||
| Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen | Q41196307 | ||
| Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities | Q41891308 | ||
| Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors | Q42029476 | ||
| Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial | Q42851077 | ||
| Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease | Q44493549 | ||
| SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. | Q44772939 | ||
| Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Mol | Q51027001 | ||
| Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. | Q53381394 | ||
| Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. | Q53532627 | ||
| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. | Q54258510 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 199-208 | |
| P577 | publication date | 2016-10-28 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression | |
| P478 | volume | 129 |
| Q90116040 | Bone marrow microenvironment: The guardian of leukemia stem cells |
| Q61796550 | C/EBPβ is a critical mediator of IFN-α-induced exhaustion of chronic myeloid leukemia stem cells |
| Q57821741 | Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation |
| Q38684223 | Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches. |
| Q92282773 | Chronic myeloid leukemia stem cells |
| Q54979166 | Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia. |
| Q33593877 | Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission |
| Q92282719 | Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies |
| Q90950090 | JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models |
| Q91812801 | Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update |
| Q90218846 | Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation |
| Q59336102 | Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis |
| Q89710631 | Prospects for achieving treatment-free remission in chronic myeloid leukaemia |
| Q91738617 | Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells |
| Q93108227 | Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment |
| Q52375473 | Targeting Leukemia Stem Cells in the Bone Marrow Niche. |
| Q90152854 | The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective |
| Q55396890 | Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. |
Search more.